Orexigen Signs Licensing Agreement With GSK
Published: 11-Jun-2009
To submit NDA in the first half of 2010
California-based Orexigen has announced the licensing of certain intellectual property (IP) from GlaxoSmithKline (GSK), that expands the company's IP position underlying Contrave, its lead product candidate for the treatment of obesity.
Financial details were undisclosed yet.
Orexigen has secured non-exclusive rights to certain formulation patents related to bupropion, one of the constituents of Contrave. The transaction is not expected to materially impact the company's financial position.
Earlier, top line results for the first of four phase-III clinical trials for Contrave, NB-302, were announced in January 2009. Results from the three other phase-III clinical trials (NB-301, NB-303, NB-304) are expected to be announced in the third quarter of 2009. The company expects to submit a New Drug Application (NDA) with the FDA in the first half of 2010.
Michael Narachi, President and CEO of Orexigen, said: This license agreement with GSK complements the IP foundation of Contrave, providing us with additional product formulation options as we pursue regulatory approval and potential commercialization of Contrave.”
Delicious
Digg
Reddit
Stumble
Facebook
LinkedInNetwork Sites
Mail sent successfully
Suppliers To This Sector
Browse A-Z
World Courier
Offering Fully-Integrated GxP-Compliant Global Transport and Storage for the Pharmaceutical Industry...
WebWise Learning
Turning Information into Working Knowledge ...
Vetter Pharma International
High-Quality Aseptically Pre-Filled Injection Systems, Cartridges and Vials ...
Valsynthese
Hazardous Chemistry in Safe Hands ...
USB
Products from Affymetrix ...
Umicore Precious Metals Chemistry
Chemicals and Catalysts for Industrial Applications ...
White Papers
Browse A-Z
Your IP at Risk in Collaborations!
Free white paper: Ten steps to protect your R&D investment within partnerships. ...
Why, When and How to Conduct 14C Human Studies
Several risk-based strategies to assess metabolites exist. Whatever the strategy chosen, t ...
Why CAPA Still Matters
This free white paper explores the needs and effectiveness of correct CAPA control, how to ...
Water Treatment
From the control room to the downstream processing area and with an eye on utilities servi ...
Using the Mean Kinetic Temperature (MKT) As a Parameter to Determine Whether Perishable Goods Have Been Transported and Stored Correctly
Tecnosoft systems use MKT calculation to control the acquired values and report the user w ...
USB HotStart-IT for Real Time PCR
USB® Products from Affymetrix have a long-standing reputation in the life science marketpl ...
